{"success":true,"data":{"pressRelease":{"id":"21525","rtpr_id":"nGNE7lYB8L","ticker":"VLS","exchange":"Euronext Paris","all_tickers":["VLS"],"title":"REG-Valneva to Report First Quarter 2026 Consolidated Financial Results on May 13, 2026","author":"Globe Newswire","published_at":"2026-05-05T15:45:00.158Z","article_body":"Lyon (France), May 05, 2026 – Valneva SE\n(https://www.globenewswire.com/Tracker?data=nHP-qe1UEBcyU_POPM81gsHi2GfnnlnR1lra4PTiSzILi6M2p6soSdTD24UWEcJnxjjVIqu0OYWfu0QrKzMYHg==)\n(Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today\nannounced that it will report its first quarter 2026 financial results on\nWednesday, May 13, 2026. The Company will host a live webcast beginning at 3\np.m. CET/9 a.m. ET to discuss the financial results and provide a business\nupdate.\n\nThe live webcast will be accessible on the Company’s website and made\navailable as an archive after the event concludes. Please refer to this link:\nhttps://edge.media-server.com/mmc/p/xbkzgkz7\n\nAbout Valneva SE\nWe are a specialty vaccine company that develops, manufactures, and\ncommercializes prophylactic vaccines for infectious diseases addressing unmet\nmedical needs. We take a highly specialized and targeted approach, applying\nour deep expertise across multiple vaccine modalities, focused on providing\neither first-, best- or only-in-class vaccine solutions. We have a strong\ntrack record, having advanced multiple vaccines from early R&D to approvals,\nand currently market three proprietary travel vaccines. \nRevenues from our growing commercial business help fuel the continued\nadvancement of our vaccine pipeline. This includes the only Lyme disease\nvaccine candidate in advanced clinical development, which is partnered with\nPfizer, the world’s most clinically advanced Shigella vaccine candidate, as\nwell as vaccine candidates against other global public health threats. More\ninformation is available on the Company’s website.\n\n Valneva Investor and Media Contacts Laetitia Bachelot-Fontaine VP, Global Communications and European Investor Relations M +33 (0)6 4516 7099 Laetitia.BachelotFontaine@valneva.com  Joshua Drumm, Ph.D. VP, Global Investor Relations M +001 917 815 4520 joshua.drumm@valneva.com      \n\nForward-Looking Statements\n\nThis press release contains certain forward-looking statements relating to the\nbusiness of Valneva, including with respect to business partnerships and the\nprogress, timing, results and completion of technology transfer and regulatory\napprovals in additional markets. In addition, even if the actual results or\ndevelopment of Valneva are consistent with the forward-looking statements\ncontained in this press release, those results or developments of Valneva may\nnot be sustained in the future. In some cases, you can identify\nforward-looking statements by words such as “could,” “should,”\n“may,” “expects,” “anticipates,” “believes,” “intends,”\n“estimates,” “aims,” “targets,” or similar words. These\nforwardlooking statements are based largely on the current expectations of\nValneva as of the date of this press release and are subject to a number of\nknown and unknown risks and uncertainties and other factors that may cause\nactual results, performance or achievements to be materially different from\nany future results, performance or achievement expressed or implied by these\nforward-looking statements. In particular, the expectations of Valneva could\nbe affected by, among other things, uncertainties and delays involved in the\ndevelopment and manufacture of vaccines, unexpected clinical trial results,\nunexpected regulatory actions or delays, competition in general, currency\nfluctuations, the impact of the global and European credit crisis, and the\nability to obtain or maintain patent or other proprietary intellectual\nproperty protection. Success in preclinical studies or earlier clinical trials\nmay not be indicative of results in future clinical trials. In light of these\nrisks and uncertainties, there can be no assurance that the forward-looking\nstatements made in this press release will in fact be realized. Valneva is\nproviding this information as of the date of this press release and disclaims\nany intention or obligation to publicly update or revise any forward-looking\nstatements, whether as a result of new information, future events, or\notherwise.\n\nAttachment\n*     2026_05_05_Q1_2026_Results_Curtain Raiser_EN_Final\n(https://ml-eu.globenewswire.com/Resource/Download/8268721f-4935-4a92-bcaf-68adad2db9c1)","article_body_html":"","raw_payload":{"data":{"id":"nGNE7lYB8L","title":"REG-Valneva to Report First Quarter 2026 Consolidated Financial Results on May 13, 2026","author":"Globe Newswire","ticker":"VLS","created":"2026-05-05T15:45:00.158Z","tickers":["VLS"],"exchange":"Euronext Paris","article_body":"Lyon (France), May 05, 2026 – Valneva SE\n(https://www.globenewswire.com/Tracker?data=nHP-qe1UEBcyU_POPM81gsHi2GfnnlnR1lra4PTiSzILi6M2p6soSdTD24UWEcJnxjjVIqu0OYWfu0QrKzMYHg==)\n(Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today\nannounced that it will report its first quarter 2026 financial results on\nWednesday, May 13, 2026. The Company will host a live webcast beginning at 3\np.m. CET/9 a.m. ET to discuss the financial results and provide a business\nupdate.\n\nThe live webcast will be accessible on the Company’s website and made\navailable as an archive after the event concludes. Please refer to this link:\nhttps://edge.media-server.com/mmc/p/xbkzgkz7\n\nAbout Valneva SE\nWe are a specialty vaccine company that develops, manufactures, and\ncommercializes prophylactic vaccines for infectious diseases addressing unmet\nmedical needs. We take a highly specialized and targeted approach, applying\nour deep expertise across multiple vaccine modalities, focused on providing\neither first-, best- or only-in-class vaccine solutions. We have a strong\ntrack record, having advanced multiple vaccines from early R&D to approvals,\nand currently market three proprietary travel vaccines. \nRevenues from our growing commercial business help fuel the continued\nadvancement of our vaccine pipeline. This includes the only Lyme disease\nvaccine candidate in advanced clinical development, which is partnered with\nPfizer, the world’s most clinically advanced Shigella vaccine candidate, as\nwell as vaccine candidates against other global public health threats. More\ninformation is available on the Company’s website.\n\n Valneva Investor and Media Contacts Laetitia Bachelot-Fontaine VP, Global Communications and European Investor Relations M +33 (0)6 4516 7099 Laetitia.BachelotFontaine@valneva.com  Joshua Drumm, Ph.D. VP, Global Investor Relations M +001 917 815 4520 joshua.drumm@valneva.com      \n\nForward-Looking Statements\n\nThis press release contains certain forward-looking statements relating to the\nbusiness of Valneva, including with respect to business partnerships and the\nprogress, timing, results and completion of technology transfer and regulatory\napprovals in additional markets. In addition, even if the actual results or\ndevelopment of Valneva are consistent with the forward-looking statements\ncontained in this press release, those results or developments of Valneva may\nnot be sustained in the future. In some cases, you can identify\nforward-looking statements by words such as “could,” “should,”\n“may,” “expects,” “anticipates,” “believes,” “intends,”\n“estimates,” “aims,” “targets,” or similar words. These\nforwardlooking statements are based largely on the current expectations of\nValneva as of the date of this press release and are subject to a number of\nknown and unknown risks and uncertainties and other factors that may cause\nactual results, performance or achievements to be materially different from\nany future results, performance or achievement expressed or implied by these\nforward-looking statements. In particular, the expectations of Valneva could\nbe affected by, among other things, uncertainties and delays involved in the\ndevelopment and manufacture of vaccines, unexpected clinical trial results,\nunexpected regulatory actions or delays, competition in general, currency\nfluctuations, the impact of the global and European credit crisis, and the\nability to obtain or maintain patent or other proprietary intellectual\nproperty protection. Success in preclinical studies or earlier clinical trials\nmay not be indicative of results in future clinical trials. In light of these\nrisks and uncertainties, there can be no assurance that the forward-looking\nstatements made in this press release will in fact be realized. Valneva is\nproviding this information as of the date of this press release and disclaims\nany intention or obligation to publicly update or revise any forward-looking\nstatements, whether as a result of new information, future events, or\notherwise.\n\nAttachment\n*     2026_05_05_Q1_2026_Results_Curtain Raiser_EN_Final\n(https://ml-eu.globenewswire.com/Resource/Download/8268721f-4935-4a92-bcaf-68adad2db9c1)"},"type":"article","timestamp":"2026-05-05T15:45:00.292613175Z","server_sent_at_ms":1777995900292},"received_at":"2026-05-05T15:45:00.385Z","source_url":null},"analysis":{"id":"17579","press_release_id":"21525","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":[],"eventType":"earnings","narrative":"Valneva SE scheduled the release of its first quarter 2026 financial results for Wednesday, May 13, 2026, with a live webcast to follow at 9 a.m. ET.\n\nThe company remains a specialty vaccine firm focused on prophylactic vaccines for infectious diseases, with a partnered Lyme disease candidate alongside Pfizer.\n\nAn archive of the webcast will be available on the company's website following the event.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Routine earnings calendar update."},"keyFigures":{},"quotedText":"","namedEntities":{"people":[{"name":"Laetitia Bachelot-Fontaine","role":"VP, Global Communications and European Investor Relations"},{"name":"Joshua Drumm, Ph.D.","role":"VP, Global Investor Relations"}],"products":["Lyme disease vaccine candidate","Shigella vaccine candidate"],"companies":[{"name":"Valneva SE","ticker":"VALN"},{"name":"Pfizer","relationship":"partner"}],"dollarAmounts":[]},"materialImpact":{"score":1,"reasoning":"This is a standard earnings pre-announcement. No financial results, guidance, or material business updates are disclosed in the release itself; it only schedules the future date for the Q1 2026 report and webcast."},"tickerRelevance":{"others":[{"ticker":"VALN","relevance":"primary"},{"ticker":"VLA","relevance":"primary"}],"primary":"VLS"},"globalImportance":10,"audienceRelevance":15,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"small-cap","eventGravity":"earnings-scheduling"}},"event_type":"earnings","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"Valneva SE scheduled the release of its first quarter 2026 financial results for Wednesday, May 13, 2026, with a live webcast to follow at 9 a.m. ET.\n\nThe company remains a specialty vaccine firm focused on prophylactic vaccines for infectious diseases, with a partnered Lyme disease candidate alongside Pfizer.\n\nAn archive of the webcast will be available on the company's website following the event.","key_figures":{},"named_entities":{"people":[{"name":"Laetitia Bachelot-Fontaine","role":"VP, Global Communications and European Investor Relations"},{"name":"Joshua Drumm, Ph.D.","role":"VP, Global Investor Relations"}],"products":["Lyme disease vaccine candidate","Shigella vaccine candidate"],"companies":[{"name":"Valneva SE","ticker":"VALN"},{"name":"Pfizer","relationship":"partner"}],"dollarAmounts":[]},"model_name":"glm-4.7","prompt_hash":"sha256:1a3f9f8af9328a99","schema_hash":"sha256:dc6ca59cd3b6e100","created_at":"2026-05-06T19:12:46.433Z","global_importance":10,"audience_relevance":15,"importance_components":{"tickerTier":"small-cap","eventGravity":"earnings-scheduling"}},"durationMs":null,"modelName":"glm-4.7"}}